Transcriptional Targeting of Glioblastoma by Diphtheria Toxin-A Driven by Both H19 and IGF2-P4 Promoters

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2012 May 9

PMID 22567173

Citations 15

Authors

Doron Amit

Imad J Matouk

Iris Lavon

Tatiana Birman

Jenifer Galula

Rasha Abu-Lail

Tamar Schneider

Tali Siegal

Abraham Hochberg

Yakov Fellig

Affiliations

Soon will be listed here.

Abstract

Background: The H19-IGF2 locus is either highly expressed and/or shows aberrant allelic pattern of expression in a large array of human cancers, while rarely expressed in the corresponding normal tissue. Preclinical, clinical studies and human compassionate using a DNA plasmid containing H19 and/or IGF2-P4 regulatory sequences that drive the expression of an intracellular toxin [diphtheria toxin A-fragment (DTA)] have demonstrated promising results in several types of carcinomas. Recently we reported that a single construct that expresses DTA under the control of both H19 and IGF2 P4 promoters showed superior efficacy in vitro as well as in vivo, in comparison to a single promoter construct in bladder carcinoma. Here we extended this approach to glioblastoma and tested the antitumor efficacy of the double promoter DTA-expressing vector (H19-DTA-P4-DTA) in vitro as well as in heterotopic animal model. H19 gene expression was tested by in-situ hybridization (ISH) and by quantitative Real-Time PCR (qRT-PCR) in samples of diffuse glioma.

Methods: IGF2-P4 gene expression was tested by qRT-PCR as well.

Results: Both H19 and IGF2-P4 transcripts were highly expressed in high grade gliomas. Furthermore, significant H19 expression in other types of primary brain tumors as well as in brain metastases was detected by ISH. Both A172 and U87 human glioblastoma cell lines showed high expression of IGF2-P4 while the A172 cell line showed high expression of H19 RNA as well. H19-DTA-P4-DTA exhibited superior cytotoxic activity compared to the single promoter expression vectors, in U87 and A172 glioblastoma cell lines in vitro and showed antitumoral efficacy in heterotopic glioblastoma animal model.

Conclusions: Our findings indicate antitumoral efficacy against glioblastoma of the targeted double promoter vector H19-DTA-P4-DTA, both in-vitro and in-vivo. Thus, its test in orthotopic animal model of glioblastoma as well as in clinical trials is warranted.

Citing Articles

Genomic, epigenomic and transcriptomic landscape of glioblastoma.

Dakal T, Kakde G, Maurya P Metab Brain Dis. 2024; 39(8):1591-1611.

PMID: 39180605 DOI: 10.1007/s11011-024-01414-8.

Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma.

Xie G, Shan L, Liu Y, Wu T, Gu X Biology (Basel). 2022; 11(4).

PMID: 35453686 PMC: 9027470. DOI: 10.3390/biology11040486.

Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies.

Karlsson J, Luly K, Tzeng S, Green J Adv Drug Deliv Rev. 2021; 179:113999.

PMID: 34715258 PMC: 8720292. DOI: 10.1016/j.addr.2021.113999.

Long non-coding RNA NBAT1 inhibits the progression of glioma through the miR-21/SOX7 axis.

Guan N, Wang R, Feng X, Li C, Guo W Oncol Lett. 2020; 20(3):3024-3034.

PMID: 32782620 PMC: 7400975. DOI: 10.3892/ol.2020.11847.

Long non-coding RNA LINC01426 facilitates glioblastoma progression via sponging miR-345-3p and upregulation of VAMP8.

Cao J, Tang Z, Su Z Cancer Cell Int. 2020; 20:327.

PMID: 32699526 PMC: 7372762. DOI: 10.1186/s12935-020-01416-3.

References

Ayesh S, Matouk I, Schneider T, Ohana P, Laster M, de-Groot N . Possible physiological role of H19 RNA. Mol Carcinog. 2002; 35(2):63-74. DOI: 10.1002/mc.10075. View

Albrecht S, Waha A, Koch A, Kraus J, Goodyer C, Pietsch T . Variable imprinting of H19 and IGF2 in fetal cerebellum and medulloblastoma. J Neuropathol Exp Neurol. 1996; 55(12):1270-6. DOI: 10.1097/00005072-199612000-00011. View

Liu T, Willingham M, Tatter S, Cohen K, Lowe A, Thorburn A . Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug Chem. 2003; 14(6):1107-14. DOI: 10.1021/bc034111+. View

Laske D, Youle R, Oldfield E . Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997; 3(12):1362-8. DOI: 10.1038/nm1297-1362. View

Amit D, Hochberg A . Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. J Transl Med. 2010; 8:134. PMC: 3016259. DOI: 10.1186/1479-5876-8-134. View

Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner P . CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007; 67(9):4010-5. DOI: 10.1158/0008-5472.CAN-06-4180. View

Matouk I, Mezan S, Mizrahi A, Ohana P, Abu-Lail R, Fellig Y . The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta. 2010; 1803(4):443-51. DOI: 10.1016/j.bbamcr.2010.01.010. View

Wu H, Squire J, Catzavelos C, Weksberg R . Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas. Biochem Biophys Res Commun. 1997; 235(1):123-9. DOI: 10.1006/bbrc.1997.6744. View

Fellig Y, Ariel I, Ohana P, Schachter P, Sinelnikov I, Birman T . H19 expression in hepatic metastases from a range of human carcinomas. J Clin Pathol. 2005; 58(10):1064-8. PMC: 1770739. DOI: 10.1136/jcp.2004.023648. View

10.

Holthuizen P, van der Lee F, Ikejiri K, Yamamoto M, Sussenbach J . Identification and initial characterization of a fourth leader exon and promoter of the human IGF-II gene. Biochim Biophys Acta. 1990; 1087(3):341-3. DOI: 10.1016/0167-4781(90)90010-y. View

11.

Hall W, Sherr G . Convection-enhanced delivery of targeted toxins for malignant glioma. Expert Opin Drug Deliv. 2006; 3(3):371-7. DOI: 10.1517/17425247.3.3.371. View

12.

Engebraaten O, Hjortland G, Juell S, Hirschberg H, Fodstad O . Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer. 2002; 97(6):846-52. DOI: 10.1002/ijc.10137. View

13.

Weaver M, Laske D . Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003; 65(1):3-13. DOI: 10.1023/a:1026246500788. View

14.

Ferguson S, Foster K, Yamini B . Convection-enhanced delivery for treatment of brain tumors. Expert Rev Anticancer Ther. 2008; 7(12 Suppl):S79-85. DOI: 10.1586/14737140.7.12s.S79. View

15.

Ohana P, Bibi O, Matouk I, Levy C, Birman T, Ariel I . Use of H19 regulatory sequences for targeted gene therapy in cancer. Int J Cancer. 2002; 98(5):645-50. DOI: 10.1002/ijc.10243. View

16.

Corcoran R, Bachar Raveh T, Barakat M, Lee E, Scott M . Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous mice. Cancer Res. 2008; 68(21):8788-95. PMC: 2597356. DOI: 10.1158/0008-5472.CAN-08-2135. View

17.

Sidi A, Ohana P, Benjamin S, Shalev M, Ransom J, Lamm D . Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol. 2008; 180(6):2379-83. DOI: 10.1016/j.juro.2008.08.006. View

18.

Kawase A, Nomura T, Yasuda K, Kobayashi N, Hashida M, Takakura Y . Disposition and gene expression characteristics in solid tumors and skeletal muscle after direct injection of naked plasmid DNA in mice. J Pharm Sci. 2003; 92(6):1295-304. DOI: 10.1002/jps.10392. View

19.

Morford L, Boghaert E, Brooks W, Roszman T . Insulin-like growth factors (IGF) enhance three-dimensional (3D) growth of human glioblastomas. Cancer Lett. 1997; 115(1):81-90. DOI: 10.1016/s0304-3835(97)04717-4. View

20.

Griguer C, Oliva C, Gobin E, Marcorelles P, Benos D, Lancaster Jr J . CD133 is a marker of bioenergetic stress in human glioma. PLoS One. 2008; 3(11):e3655. PMC: 2577012. DOI: 10.1371/journal.pone.0003655. View